Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc R de Jonge

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Medicinal Chemistry|March 18, 2005
Genotype dependent QSAR for HIV-1 protease inhibitionCarlo W Boutton, Hendrik L De Bondt, Marc R De Jonge
Proteins|March 28, 2007
A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910Marc R de Jonge, Luc H M Koymans, Jérôme E G Guillemont, et al.
Journal of Medicinal Chemistry|March 18, 2005
Structure based activity prediction of HIV-1 reverse transcriptase inhibitorsMarc R de Jonge, Lucien M H Koymans, H Maarten Vinkers, et al.
Journal of Medicinal Chemistry|June 13, 2003
SYNOPSIS: SYNthesize and OPtimize System in SilicoH Maarten Vinkers, Marc R de Jonge, Frederik F D Daeyaert, et al.
Journal of Medicinal Chemistry|March 18, 2005
Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1Jerome Guillemont, Elisabeth Pasquier, Patrice Palandjian, et al.
Journal of Medicinal Chemistry|March 18, 2005
Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activityJan Heeres, Marc R de Jonge, Lucien M H Koymans, et al.
Journal of Medicinal Chemistry|April 30, 2004
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variantsKalyan Das, Arthur D Clark, Paul J Lewi, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Medicinal Chemistry|March 18, 2005
Genotype dependent QSAR for HIV-1 protease inhibitionCarlo W Boutton, Hendrik L De Bondt, Marc R De Jonge
Proteins|March 28, 2007
A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910Marc R de Jonge, Luc H M Koymans, Jérôme E G Guillemont, et al.
Journal of Medicinal Chemistry|March 18, 2005
Structure based activity prediction of HIV-1 reverse transcriptase inhibitorsMarc R de Jonge, Lucien M H Koymans, H Maarten Vinkers, et al.
Journal of Medicinal Chemistry|June 13, 2003
SYNOPSIS: SYNthesize and OPtimize System in SilicoH Maarten Vinkers, Marc R de Jonge, Frederik F D Daeyaert, et al.
Journal of Medicinal Chemistry|March 18, 2005
Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1Jerome Guillemont, Elisabeth Pasquier, Patrice Palandjian, et al.
Journal of Medicinal Chemistry|March 18, 2005
Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activityJan Heeres, Marc R de Jonge, Lucien M H Koymans, et al.
Journal of Medicinal Chemistry|April 30, 2004
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variantsKalyan Das, Arthur D Clark, Paul J Lewi, et al.
Pageof 1